Gedea Biotech granted European Patent for the formulation of its vaginal pHyph tablet for women with vaginal infections
· Further strengthens Gedea Biotech’s broad patent portfolio · pHyph has demonstrated a superior safety profile, a cure rate in line with antibiotics and a lower infection recurrence rate · Additionally, unlike antibiotics, pHyph will not promote antimicrobial resistance Lund, Sweden, September 13, 2023. Swedish women’s health company Gedea Biotech announced today that the European Patent Office (EPO) has granted the company´s patent application no. 20715885.8 for the formulation of the active ingredient, Glucone-delta lactone (GDL) in pHyph™, the company’s vaginal tablet for